JUNS (Jupiter Neurosciences Inc) EV/EBITDA Multiple
The share price of Jupiter Neurosciences Inc (JUNS) visualized below on GURU.Markets, where the EV/EBITDA ratio stands at 0.00, highlights the risks of limited capital and the uncertainty surrounding Alzheimer's drug trials. Jupiter Neurosciences Inc is focused on developing JPC-033, an enhanced resveratrol designed to combat neuronal decay. However, the business faces skepticism from regulatory bodies regarding plant-based formulas and intense pressure from traditional pharmaceutical behemoths.
Comprehensive metric breakdowns and analytics for Jupiter Neurosciences, Inc. (JUNS)
- market price and analyst price targets:
- business market valuation indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Debt to Equity Jupiter Neurosciences Inc|JUNS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Jupiter Neurosciences Inc|JUNS - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Jupiter Neurosciences Inc|JUNS - Company Long-Term Indebtedness|Company Short-Term Debts Jupiter Neurosciences|Quick Liquidity Indicator jupiterneurosciences.com
- net income and valuation multiples indicators:
JUNS - Net Profit|Expected Profit Jupiter Neurosciences Inc|JUNS - Company Value to Net Income|Future Price to Earnings Jupiter Neurosciences|JUNS - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jupiter Neurosciences Inc|JUNS - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Jupiter Neurosciences|JUNS - Net earnings per share for the last 12 months|Quarterly EPS earnings growth jupiterneurosciences.com|JUNS - Expected net earnings per share growth this year|Earnings growth forecast for next year Jupiter Neurosciences Inc
Summary company analysis:JUNS (Jupiter Neurosciences)
The EV/EBITDA multiple determines the total value of a business relative to its operating profit before depreciation and amortization, allowing for an assessment of company efficiency regardless of debt load or tax regime. By analyzing the historical EV/EBITDA chart for Jupiter Neurosciences Inc. (JUNS), an investor can track the impact of drug delivery system development costs and production diversification on the enterprise's overall capitalization.
Competitor analysis for Jupiter Neurosciences Inc
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|NBIX (Neurocrine Corp) - Company Value to Operating Income Before Depreciation Ratio|Regencell Bioscience - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio axsome.com AXSM|ACAD (ACADIA Pharmaceuticals Inc.) - Enterprise Value to EBITDA Ratio|XENE: Enterprise Value to Operating Income Before Depreciation Ratio|VKTX (Viking Pharma) - EV/EBITDA Multiple|Company Value to EBITDA Supernus Corp SUPN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catalyst Pharmaceuticals (CPRX)|DNLI (denalitherapeutics.com) - Business Value to Operating Income Before Depreciation|Harmony Biosciences Holdings, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BHVN|AMLX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TRVI (Trevi Corp) - Enterprise Value to Operating Income Before Depreciation|PRAX: EV/EBITDA Multiple|Company Value to EBITDA anavex.com (AVXL)|Enterprise Value to EBITDA Ratio CBLL|EV/EBITDA Multiple Prothena Corporation PLC|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alector, Inc. (ALEC)|ANNX (Annexon Biosciences Inc.) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omeros OMER|neurogene.com (NGNE) - Company Value to EBITDA|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Voyager Therapeutics Inc VYGR|NMRA: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Scilex Holding Company, Inc.|TVGN (Tevogen Bio Holdings) - EV/EBITDA Multiple|Alpha Cognition Corp (ACOG) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CGTX|IKT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cassava SAVA|ASRT: Enterprise Value to Operating Income Before Depreciation|Coya - EV/EBITDA Multiple|Vistagen Therapeutics (VTGN) - Enterprise Value to EBITDA Ratio|OVID: EV/EBITDA Multiple|Company Value to EBITDA Acumen Pharmaceuticals Inc. (ABOS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CervoMed Inc|Alterity Therapeutics Ltd (ATHE) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio CLNN (Clene Inc.)|PEPG (pepgen.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple RLMD (Relmada Therapeutics, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Annovis Bio Inc (ANVS)|GRCE - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|AIFF (Firefly Neuro) - Enterprise Value to Operating Income Before Depreciation|KLTO: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio NeuroSense Therapeutics Ltd.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Reviva Pharmaceuticals Holdings, Inc.|MTVA (MetaVia, Inc.) - Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio NRXS (NeurAxis, Inc)|EV/EBITDA Multiple heliusmedical.com (HSDT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Passage Bio PASG|NEUP: Enterprise Value to Operating Income Before Depreciation|NERV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Athira Pharma Inc ATHA|Addex Therapeutics, Ltd. (ADXN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation ALZN|CYCN (Cyclerion Therapeutics Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Protagenic PTIX|Enterprise Value to EBITDA Ratio KTTA (Pasithea Therapeutics)|EV/EBITDA Multiple cortigent.com (CRGT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avenue Therapeutics, Inc ATXI|Business Value to Operating Income Before Depreciation BCLI|CARA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA chromocell.com|eliemtx.com (ELYM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ITCI: Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio LBPH|EV/EBITDA Multiple Marinus Pharma|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NKGen Biotech, Inc. (NKGN)|NRBO: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple SAGE (Sage Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio Synaptogenix Inc. (SNPX)|TRVN: Enterprise Value to EBITDA Ratio|Vigil Neuroscience - Enterprise Value to Operating Income Before Depreciation Ratio|WENA: EV/EBITDA Multiple|Company Value to EBITDA cerevel.com (CERE)
